- Home
- NNAVW vs DVAX Comparison
NNAVW vs DVAX Comparison
Compare NNAVW & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNAVW
- DVAX
- Stock Information
- Founded
- NNAVW 2007
- DVAX 1996
- Country
- NNAVW United States
- DVAX United States
- Employees
- NNAVW 96
- DVAX N/A
- Industry
- NNAVW Industrial Machinery/Components
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- NNAVW Industrials
- DVAX Health Care
- Exchange
- NNAVW Nasdaq
- DVAX Nasdaq
- Market Cap
- NNAVW N/A
- DVAX 1.2B
- IPO Year
- NNAVW N/A
- DVAX 2004
- Fundamental
- Price
- NNAVW $4.37
- DVAX $9.83
- Analyst Decision
- NNAVW
- DVAX Buy
- Analyst Count
- NNAVW 0
- DVAX 4
- Target Price
- NNAVW N/A
- DVAX $26.50
- AVG Volume (30 Days)
- NNAVW 53.1K
- DVAX 1.3M
- Earning Date
- NNAVW 03-12-2025
- DVAX 11-06-2025
- Dividend Yield
- NNAVW N/A
- DVAX N/A
- EPS Growth
- NNAVW N/A
- DVAX N/A
- EPS
- NNAVW N/A
- DVAX N/A
- Revenue
- NNAVW $4,963,000.00
- DVAX $316,268,000.00
- Revenue This Year
- NNAVW N/A
- DVAX $23.23
- Revenue Next Year
- NNAVW N/A
- DVAX $16.57
- P/E Ratio
- NNAVW N/A
- DVAX N/A
- Revenue Growth
- NNAVW 43.44
- DVAX 26.66
- 52 Week Low
- NNAVW $4.47
- DVAX $9.20
- 52 Week High
- NNAVW $4.70
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- NNAVW 26.22
- DVAX 44.18
- Support Level
- NNAVW $4.83
- DVAX $9.71
- Resistance Level
- NNAVW $5.24
- DVAX $10.12
- Average True Range (ATR)
- NNAVW 0.37
- DVAX 0.26
- MACD
- NNAVW -0.13
- DVAX -0.01
- Stochastic Oscillator
- NNAVW 7.95
- DVAX 26.97
About NNAVW NextNav Inc. Warrant
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.